PEPTIDES4ALL Cagrilintide + Retatrutide – Multi-Receptor Peptide Co-Agonist for Metabolic & Obesity Research

PEPTIDES4ALL Cagrilintide + Retatrutide is a specially formulated peptide combination that pairs Cagrilintide, a long-acting amylin and calcitonin receptor agonist, with Retatrutide, a cutting-edge triple-receptor (GIP / GLP-1 / glucagon) agonist. This blend is engineered to provide researchers with a high-potency, multi-target model for exploring advanced metabolic pathways including satiety, energy expenditure, lipid oxidation, insulin sensitivity, and adipose/organ modulation in obesity, metabolic syndrome, and endocrine research contexts.
By activating both the amylin/calcitonin axis (via Cagrilintide) and the incretin/glucagon receptor systems (via Retatrutide), this formulation enables investigation of complementary hormonal circuits—bridging gut–brain satiety signalling, pancreatic β-cell responsiveness, hepatic and adipose tissue metabolism, and whole-body energy homeostasis. Emerging data from Retatrutide studies show exceptional weight-loss depth and durability, while Cagrilintide trials demonstrate enhanced satiety, lean-mass preservation, and metabolic steering in experimental models.
This multi-hormonal approach represents the frontier of peptide engineering for metabolic research, offering a robust platform for translational models of obesity, insulin resistance, non-alcoholic fatty liver disease (NAFLD), and peptide-based endocrine therapy design.

Scientific Evidence & Research Findings

• High-Depth Weight Reduction Potential – In early phase-2 trials of Retatrutide, participants showed weight-losses up to ~30% or more in some cases over months of therapy. MedPath+2New England Journal of Medicine+2

• Cagrilintide Weight-Loss Efficacy – In a phase-2 study, weekly Cagrilintide as monotherapy in overweight/obesity achieved meaningful weight reductions and was well tolerated. PubMed

• Mechanistic Multi-Hormonal Synergy – Retatrutide’s combined GIP/GLP-1/glucagon agonism and Cagrilintide’s amylin/calcitonin receptor activation create a multi-axis metabolic model for appetite, energy expenditure and adipose modulation. Amazing Meds+1

• Emerging Organ-/Metabolic-System Benefits – Early research suggests triple-receptor peptides may improve hepatic fat, lipids, and metabolic tissue responses in fatty-liver and obesity-related models. WebMD+1

Key Research Benefits & Applications

• Multi-Receptor Co-Agonism: Simultaneous engagement of amylin/calcitonin, GIP, GLP-1 and glucagon pathways for comprehensive metabolic regulation.

• Next-Gen Weight-Management Model: Enables studies of profound fat-mass reduction, appetite suppression, energy-expenditure shift, and lean-mass preservation.

• Glucose, Insulin & Lipid Modulation: Facilitates research into β-cell responsiveness, insulin sensitivity, adipose lipid turnover and hepatic metabolism.

• Energy Homeostasis & Satiety Signalling: Combines gut–brain pathways (via Cagrilintide) with incretin and glucagon axes (via Retatrutide) for full-system modelling of metabolic shifting.

• Peptide Engineering & Translational Utility: Ideal for research into multi-agonist peptide design, receptor-bias modelling, endocrine therapy innovation, and translational metabolic science.

Presentation & Handling

• Form: Supplied as lyophilized peptide in sterile vial.
• Reconstitution: Use bacteriostatic water or 2% procaine; swirl gently (do not shake vigorously).
• Storage: Store at –20 °C, protected from light and moisture. After reconstitution, use according to research protocols and handle under sterile conditions.

Intended Use

For research purposes only. Must be handled in accordance with institutional protocols and ethical guidelines.